High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
As Tracky launches integrated health solution
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
Capital infusion to accelerate Earendil’s R&D platform
The timing of the partnership is crucial, as Kerala’s fertility rate has dropped to approximately 1.35–1.7 children per woman, below the replacement level of 2.1
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
